EC OK's new use for Amgen's Prolia

|About: Amgen Inc. (AMGN)|By:, SA News Editor

As expected, the European Commission approves the use of Amgen's (NASDAQ:AMGN) Prolia (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.

The advisory group CHMP adopted a positive opinion backing approval in late April.

Previously: European advisory group backs expanded use for Amgen's Prolia (April 27)

Subscribe for full text news in your inbox